AI News NQ Analysis

北極星藥業-KY:股東會通過解除新任董事競業禁止限制案

NQ 評分 50/100

AI 摘要(NQ 加工版)

Polaris Pharmaceuticals-KY announced that its shareholders' meeting on May 15, 2026, approved the lifting of non-competition restrictions for new directors. The approved non-competition waiver allows directors to invest in or operate businesses that are the same as or similar to Polaris Pharmaceuticals-KY's business scope, effective immediately until their term ends. This decision was passed during the shareholders' meeting on May 15, 2026.

尚無 AI 分析資料。

常見問題

Q: 北極星藥業-KY的股東常會做出了什麼決議?
A: 股東常會通過了解除新任董事競業禁止限制的決議。
Q: 哪些董事被許可從事競業行為?
A: 被許可的董事包括陳賢哲、Digital Capital Inc.(代表人:魏少筠)以及 Mai Investment Co., Ltd.(代表人:蔡高忠)。
Q: 被許可的競業行為項目是什麼?
A: 董事被許可投資或經營與公司營業範圍相同或類似的營業項目。
Q: 競業禁止限制解除的期間是多久?
A: 此項解除限制自民國 115 年 5 月 15 日起至董事卸任為止。